Phase II clinical trials with rhizoxin in breast cancer and melanoma
1996

Rhizoxin in Breast Cancer and Melanoma

Sample size: 45 publication Evidence: low

Author Information

Author(s): A-R Hanauskel, G Catimel, S Aamdal, W ten Bokkel Huinink, R Paridaens, N Pavlidis, SB Kaye, A te Velde, J Wanders, J Verweij

Primary Institution: EORTC Early Clinical Trials Group

Hypothesis

Can rhizoxin achieve partial or complete remissions in patients with advanced breast cancer and melanoma?

Conclusion

Rhizoxin can be safely administered, but it has little activity in patients with advanced breast cancer and melanoma.

Supporting Evidence

  • Rhizoxin was administered to 45 patients across two trials.
  • Only minor responses were observed in breast cancer patients.
  • No objective remissions were noted in melanoma patients.
  • Haematological toxicities were the most common side effects.
  • Patients with prior anthracycline treatment had poorer responses.

Takeaway

Rhizoxin is a new drug that was tested on patients with breast cancer and melanoma, but it didn't work well for them.

Methodology

Patients received rhizoxin as an intravenous infusion every 3 weeks, and their responses were evaluated after at least two courses of therapy.

Limitations

The study had a small sample size and did not include patients with extensive prior treatment.

Participant Demographics

{"breast_cancer":{"total_patients":19,"male_female_ratio":"0/17","age_median":56,"age_range":"34-72"},"melanoma":{"total_patients":26,"male_female_ratio":"16/10","age_median":54,"age_range":"24-76"}}

Statistical Information

Confidence Interval

95% CI: 0-22%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication